Shire Buys Fosrenol Patent Rights for Up to $31 M
By Marius Meland · March 23, 2004, 12:00 AM EST
Shire Pharmaceuticals Group Plc, the U.K.'s third-largest drugmaker, will spend up to $31 million to buy global patent rights to its kidney-failure drug Fosrenol from AnorMED, the company said....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login